Polyclonal Antibody to Inhibitory Subunit Of NF Kappa B Beta (IkBb)
Code | Size | Price |
---|
PAB849Hu01-20ul | 20ul | £84.00 |
Quantity:
PAB849Hu01-100ul | 100ul | £155.00 |
Quantity:
PAB849Hu01-200ul | 200ul | £208.00 |
Quantity:
PAB849Hu01-1ml | 1ml | £475.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
TRIP9; NFKBIB; Thyroid receptor-interacting protein 9; Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells Inhibitor,Beta; NF-Kappa-B Inhibitor Beta
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Inhibitory Subunit Of NF Kappa B Beta
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:350-1300<br/>Immunohistochemistry: 5-20ug/mL;1:35-130<br/>Immunocytochemistry: 5-20ug/mL;1:35-130<br/>Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Inhibitory Subunit Of NF Kappa B Beta (IkBb) | RPB849Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||